Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder
NCT05370911Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- Jul 2023
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of psilocybin in obsessive compulsive disorder (OCD) (2 arms), sponsored by Yale University. Primary endpoint: Yale-Brown Obsessive-Compulsive Scale-Second Edition Severity Scale. Started Jul 2023; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT05370911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370911.